These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19965595)

  • 1. Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria.
    Yang SH; Chang SY; Andres DA; Spielmann HP; Young SG; Fong LG
    J Lipid Res; 2010 Feb; 51(2):400-5. PubMed ID: 19965595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin.
    Yang SH; Chang SY; Ren S; Wang Y; Andres DA; Spielmann HP; Fong LG; Young SG
    Hum Mol Genet; 2011 Feb; 20(3):436-44. PubMed ID: 21088111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking protein farnesylation improves nuclear shape abnormalities in keratinocytes of mice expressing the prelamin A variant in Hutchinson-Gilford progeria syndrome.
    Wang Y; Ostlund C; Worman HJ
    Nucleus; 2010; 1(5):432-9. PubMed ID: 21326826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation.
    Yang SH; Qiao X; Fong LG; Young SG
    Biochim Biophys Acta; 2008; 1781(1-2):36-9. PubMed ID: 18082640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
    Glynn MW; Glover TW
    Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation.
    Yang SH; Meta M; Qiao X; Frost D; Bauch J; Coffinier C; Majumdar S; Bergo MO; Young SG; Fong LG
    J Clin Invest; 2006 Aug; 116(8):2115-21. PubMed ID: 16862216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and pharmacological modulation of lamin A farnesylation determines its function and turnover.
    Foo MXR; Ong PF; Yap ZX; Maric M; Bong CJS; Dröge P; Burke B; Dreesen O
    Aging Cell; 2024 May; 23(5):e14105. PubMed ID: 38504487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria.
    Fong LG; Frost D; Meta M; Qiao X; Yang SH; Coffinier C; Young SG
    Science; 2006 Mar; 311(5767):1621-3. PubMed ID: 16484451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
    Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
    Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
    Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
    Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence and distribution of progerin in HGPS cells is ameliorated by drugs that impact on the mevalonate and mTOR pathways.
    Clements CS; Bikkul MU; Ofosu W; Eskiw C; Tree D; Makarov E; Kill IR; Bridger JM
    Biogerontology; 2019 Jun; 20(3):337-358. PubMed ID: 31041622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells.
    Arnold R; Vehns E; Randl H; Djabali K
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyltransferase inhibition in HGPS.
    Misteli T
    Cell; 2021 Jan; 184(2):293. PubMed ID: 33482093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation.
    Yang SH; Bergo MO; Toth JI; Qiao X; Hu Y; Sandoval S; Meta M; Bendale P; Gelb MH; Young SG; Fong LG
    Proc Natl Acad Sci U S A; 2005 Jul; 102(29):10291-6. PubMed ID: 16014412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transient introduction of human telomerase mRNA improves hallmarks of progeria cells.
    Li Y; Zhou G; Bruno IG; Zhang N; Sho S; Tedone E; Lai TP; Cooke JP; Shay JW
    Aging Cell; 2019 Aug; 18(4):e12979. PubMed ID: 31152494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model.
    Capell BC; Olive M; Erdos MR; Cao K; Faddah DA; Tavarez UL; Conneely KN; Qu X; San H; Ganesh SK; Chen X; Avallone H; Kolodgie FD; Virmani R; Nabel EG; Collins FS
    Proc Natl Acad Sci U S A; 2008 Oct; 105(41):15902-7. PubMed ID: 18838683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B.
    Odinammadu KO; Shilagardi K; Tuminelli K; Judge DP; Gordon LB; Michaelis S
    Nucleus; 2023 Dec; 14(1):2288476. PubMed ID: 38050983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes.
    Toth JI; Yang SH; Qiao X; Beigneux AP; Gelb MH; Moulson CL; Miner JH; Young SG; Fong LG
    Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12873-8. PubMed ID: 16129834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prelamin A farnesylation and progeroid syndromes.
    Young SG; Meta M; Yang SH; Fong LG
    J Biol Chem; 2006 Dec; 281(52):39741-5. PubMed ID: 17090536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing the length of progerin's isoprenyl anchor does not worsen bone disease or survival in mice with Hutchinson-Gilford progeria syndrome.
    Davies BS; Yang SH; Farber E; Lee R; Buck SB; Andres DA; Spielmann HP; Agnew BJ; Tamanoi F; Fong LG; Young SG
    J Lipid Res; 2009 Jan; 50(1):126-34. PubMed ID: 18757838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.